Cyrus Biotechnology

Cyrus Biotechnology is a privately held, computationally driven discovery company based in Seattle, Washington, United States. It focuses on naturally existing proteins that show potential to be turned into superior therapeutics using computational modeling and deep mutagenesis. The company describes its platform as proven, citing more than 30 discovery programs with partners, and positions itself around a rapid path to superior biologics engineered from natural proteins. Its integrated approach to protein design employs novel algorithms and sophisticated laboratory methods. Cyrus Bio's lead programs target severe autoimmune disease and therapeutic immuno-cytokines. Its IdeS program is an IgG-depleting agent intended to address what the company describes as over $20 billion of clinical market in IgG-driven autoimmune disease, such as generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP). A second program is a potent IL-22 variant for autoimmune gastrointestinal and metabolic indications; the IL-22 fusion protein is designed to enable superior efficacy via disinhibition against naturally occurring IL-22 binding protein. A third program, ACE2v2-Fc, is a half-life-optimized ARDS candidate: an optimized ACE2-IgG Fc fusion protein engineered for extended pharmacokinetics and pharmacology using the company's protein design and glycosylation platforms, for the treatment of acute respiratory distress syndrome. The company is backed by top-tier global investors, including some of the largest global venture capital firms in biotechnology as well as major technology investors and local seed investors in Seattle. Its leadership team combines scientific innovation with drug-development and business experience. Lucas Nivon is Chief Executive Officer; Erik Procko is Chief Scientific Officer; Mark Benjamin is President and EVP of Business Development; Eric Tarcha is SVP of Development; Yifan Song is Chief Technology Officer; and Gabor Illei is Senior Clinical Advisor. David Baker is Scientific Co-Founder and Advisor, and the scientific advisory group also includes Will Chen, Mohammed AlQuraishi, Manuel Baca, and Derek Pociask. The board includes Lucas Nivon, Yifan Song, Chad Waite, Jason Smith, Schwark Satyavolu, and Anthony Manning, with Eric Bell, Geeta Vemuri, Carl Gordon, and Eric Larsen as board observers. Members of the Cyrus scientific team have published seminal demonstrations of protein structure prediction, protein AI algorithm development, and protein/protein interaction design in numerous programs at the Institute for Protein Design (IPD) and other institutions. The team has worked on computational discovery and novel intellectual property for over 30 partner firms, including Janssen, Genentech, Nimbus, and Selecta. The executive team brings experience from multiple INDs, large business-development transactions, and biotech IPOs, complementing the scientific innovation at Cyrus. The company is active and privately held.

Cyrus Biotechnology is a Seattle-based computational protein design company. Its scientific roots lie in the protein design and protein AI community, particularly the Institute for Protein Design (IPD) and other institutions, where members of the Cyrus scientific team published some of the seminal demonstrations of protein structure prediction, protein AI algorithm development, and protein/protein interaction design. The company was founded to apply these advances commercially, building a platform that combines novel algorithms with sophisticated laboratory methods, including deep mutagenesis, to engineer naturally existing proteins into superior therapeutics. Cyrus built its business on computational discovery and novel intellectual property for partner firms. According to the company, the team has worked on more than 30 partner discovery programs, including work with Janssen, Genentech, Nimbus, and Selecta. This partner-driven service and discovery model provided a proven platform and helped establish the company's credibility in the biologics engineering space. From this platform, Cyrus advanced its own lead programs in severe autoimmune disease and therapeutic immuno-cytokines. Its IdeS program is an IgG-depleting agent aimed at IgG-driven autoimmune diseases such as generalized myasthenia gravis (gMG) and immune thrombocytopenia (ITP), which the company describes as representing over $20 billion of clinical market. A second program, a potent IL-22 variant fusion protein, targets autoimmune gastrointestinal and metabolic indications and is designed to achieve superior efficacy via disinhibition against naturally occurring IL-22 binding protein. A third program, ACE2v2-Fc, is a half-life-optimized ACE2-IgG Fc fusion protein engineered for extended pharmacokinetics and pharmacology using the company's protein design and glycosylation platforms, for the treatment of acute respiratory distress syndrome (ARDS). The company is backed by top-tier global investors, including some of the largest global venture capital firms in biotechnology, major technology investors, and local seed investors in Seattle. Its executive team brings experience from multiple INDs, large business-development transactions, and biotech IPOs. Leadership includes CEO Lucas Nivon, CSO Erik Procko, President and EVP of Business Development Mark Benjamin, SVP of Development Eric Tarcha, CTO Yifan Song, and Senior Clinical Advisor Gabor Illei. David Baker serves as Scientific Co-Founder and Advisor. The company remains privately held and active.

• Scientific team members publish seminal work on protein structure prediction, protein AI algorithm development, and protein/protein interaction design at the Institute for Protein Design (IPD) and other institutions.

• Company builds a proven platform with 30+ discovery programs for partners including Janssen, Genentech, Nimbus, and Selecta.

• Lead programs advance in severe autoimmune disease and therapeutic immuno-cytokines, including IdeS, IL-22 variant, and ACE2v2-Fc.

Computationally driven discovery company engineering natural proteins into superior biologics, with a proven platform of 30+ partner discovery programs and lead assets in autoimmune disease and immuno-cytokines.

• IdeS

  IgG-depleting agent for IgG-driven autoimmune diseases such as gMG and ITP, addressing over $20B of clinical market.

• IL-22 variant fusion protein

  Potent IL-22 variant for autoimmune gastrointestinal and metabolic indications, designed for superior efficacy via disinhibition against naturally occurring IL-22 binding protein.

• ACE2v2-Fc

  Half-life-optimized ACE2-IgG Fc fusion protein engineered for extended PK and pharmacology for treatment of Acute Respiratory Distress Syndrome.

1. 1Home - Cyrus Biotechcyrusbio.com
2. 2About - Cyrus Biotechcyrusbio.com
3. 3Cyrus Biotechnology - Wikidatawikidata.org